Keyword: biosimilars

49 results found
Proposed changes to Ontario drug rules target generics pricing, biosimilar listing process

Ontario has proposed amendments to provincial drug regulations that aim to change the pricing model for generic drugs and simplify the process for the province’s drug formulary to list biosimilars. Ontario’s Ministry of Health and Long-Term Care said the changes are aimed at reducing the “administrative burden” for drug manufacturers and pharmacies. With regards to […]

  • By: Staff
  • November 14, 2019 November 12, 2020
  • 09:00
Switch from biologic to biosimilar drug requires monitoring, patient-informed discussion

When it comes to switching from a biologic to a biosimilar drug, patient choice and engagement is extremely important, according to Durhane Wong-Rieger, president and chief executive officer of the Canadian Organization for Rare Disorders.  “While a patient’s on a drug, they need to be continuously monitoring,” she said during a session at Benefits Canada’s 2019 Calgary Drug […]

The Alberta Teachers’ Retirement Fund Board will transfer all of its funds to the Alberta Investment Management Corp., according to the province’s latest budget. The ATRF board, which administers pensions for all teachers in Alberta school jurisdictions and charter schools, said in a press release it was only made aware of the change when the budget was released […]

How employers, health-care policies can support employees with irritable bowel disease

With around 270,000 individuals currently affected by irritable bowel disease, Canada has the highest prevalence in the world, according to Mina Mawani, president and chief executive officer of Crohn’s and Colitis Canada, during a session at Benefits Canada’s 2019 Halifax Benefits Summit on Sept. 24. “And this is going to increase significantly. We’re going to be […]

Policies around transitioning to biosimilars in Europe, the U.S. and Canada

Sixty per cent of all prescriptions in Canada are paid for by employer-provided drug plans and some have life-time limits for biologic reimbursement. However, transitioning to a biosimilar could extend this limit for patients, said Dr. John Esdaile, scientific director at Arthritis Research Canada, during Benefits Canada’s Halifax Benefits Summit on Sept. 24. Biologic drugs are derived through […]

Institutional investors urging Congress to vote down CUSMA, citing effect on drug prices

A group of institutional investors representing more than US$500 billion is calling on the U.S. Congress to vote down the Canada-United States-Mexico trade agreement to prevent extended monopoly rights for pharmaceutical companies in all three countries. The Interfaith Center on Corporate Responsibility, which represents more than 300 religious institutional investors, pension funds, foundations, asset managers […]

Prescription drug costs for Canadian public plans hit $11.4 billion in 2017/18: report

Prescription drug costs for public drug plans covering most of Canada increased 7.4 per cent in 2017/18 to reach $11.4 billion, according to a new report by the Patented Medicine Prices Review Board. It’s a significant increase compared to the more modest 1.9 per cent growth in prescription drug costs from 2016/17. The board looked at data […]

  • By: Staff
  • September 12, 2019 November 12, 2020
  • 09:00
CUSMA’s data protection proposals for biologics could raise costs for private plans: PBO

If the Canada-United States-Mexico trade agreement goes through it could have a significant impact on the cost of private drug plans. Currently on hold until members of Parliament return to Ottawa after the summer break, the agreement as written would extend the data protection term for biologic drugs to 10 years from the current eight. If […]

Conference coverage: 2019 Calgary Benefits Summit

On May 22, the 2019 Calgary Benefits Summit focused on how employers can make their organization its healthiest by starting with their benefits plans. Here’s what you missed! How a Blue Zone concept can benefit the workplace What can a small Alberta town of 70,000 people do when the provincial government’s response to, “We need […]

B.C. government says expanding biosimilars will save nearly $100 million over three years

British Columbia is expanding its use of biosimilars, effective November 2019. The move is expected to create opportunities for new drug listings and increase current coverage for patients, according to a press release from the B.C. government. The first two drugs to come into immediate effect are Jardiance, a diabetes drug, and Taltz, an arthritis drug. It will change the game considerably, says Suzanne Lepage, a private […]